The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Safarova T.P.

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Iakovleva O.B.

Sheshenin V.S.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN

Kornilov V.V.

Shipilova E.S.

FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia" RAMN, Moskva

Augmentation with carnicetine for late depression

Authors:

Safarova T.P., Gavrilova S.I., Iakovleva O.B., Sheshenin V.S., Kornilov V.V., Shipilova E.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5): 65‑75

DOI: 10.17116/jnevro201911905165

Views: 1039

Downloaded: 13

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Safarova TP, Gavrilova SI, Iakovleva OB, Sheshenin VS, Kornilov VV, Shipilova ES. Augmentation with carnicetine for late depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):65‑75. (In Russ.)
https://doi.org/10.17116/jnevro201911905165

 
МСФ на ЯМ
Close metadata
Recommended articles:
The effect of inso­mnia on mild cognitive impairment in patients with vascular risks: resu­lts of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36
A perspective on the application of CRISPR/CAS9 genome editing system to study of mole­cular-genetic basis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33
Vali­dation of screening method based on EEG analysis for the risk asse­ssment of psychiatric and beha­vioral diso­rders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Pathogenetic basis of modern approaches to the therapy of sleep diso­rders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74
Features of the clinical picture of affe­ctive diso­rders in women during the meno­pausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79
Diagnostic approaches to asse­ssing mild beha­vioral impairment in patients with mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):49-55
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Evaluation of clinical mani­festations of sarcopenia in elde­rly people in the Tyumen region. Russian Journal of Preventive Medi­cine. 2024;(5):69-74

Objective. Comparative evaluation of the efficacy and safety of antidepressant monotherapy and complex antidepressant therapy in combination with carnicetine in the treatment of depression in elderly patients in a psychiatric hospital. Material and methods. Two groups of hospitalized patients, aged from 60 to 79 years, with mild or moderate depression (according to ICD-10), comparable in basic demographic and clinical characteristics, received mono- or complex (in combination with carnicetine) antidepressant therapy for 8 weeks. Treatment efficacy was assessed with HAM-D, HARS, CGI-S and CGI-I; the level of cognitive activity was assessed with MMSE, the 10-word memory test and clock drawing test. Results. It has been established that the use of complex antidepressants therapy with the inclusion of carnicetine allows to achieve a more rapid and pronounced therapeutic response compared to antidepressant monotherapy. This is confirmed by the earlier (by the 4th week) and significant reduction of depressive and anxiety symptoms (p<0.01), a greater number of responders and better quality of depressive outcomes to the end of treatment and a more rapid improvement in cognitive functioning. Conclusion. The results allow us to recommend the inclusion of carnicetine for the augmentation of antidepressant therapy in elderly patients of the psychiatric hospital to achieve a more rapid and complete therapeutic response and reduce the duration of hospitalization.

Keywords:

depression
antidepressant therapy
elderly in-patients
carnicetine

Authors:

Safarova T.P.

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Iakovleva O.B.

Sheshenin V.S.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN

Kornilov V.V.

Shipilova E.S.

FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia" RAMN, Moskva

List of references:

  1. Safarova TP, Sheshenin VS, Fedorov VV. Effektivnost’ psihofarmakoterapii u bol’nyh gerontopsihiatricheskogo stacionara s funkcional’nymi psihicheskimi rasstrojstvami. Psihiatriya. 2013;1(57):24-33. (In Russ.)
  2. Yakovleva OB. Kognitivnye narusheniya v strukture endogennyh depressij pozdnego vozrasta. Zhurnal Nevropalogii i Psihiatrii im. S.S. Korsakova. 1995;95(5):62-68. (In Russ.)
  3. Panza F, Frisardi V, Capurso C, D’Introno A, at al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psyhiatry. 2010;18:2:98-116. https://doi.org/10.1097/JGP.0b013e3181b0fa13
  4. Baldwin R, Wild R. Management of depression in later life. Advances in Psychiatric Treatment. 2004;10:131-139. https://doi.org/10.1192/apt.10.2.131
  5. Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J of Psychiatry. 2005;162:1588-1601. https://doi.org/10.1176/appi.ajp.162.9.1588
  6. Bennett MR. The prefrontal-limbic network in depression: a core pathology of synapse regression. Prog Neurobiol. 2011;93:457-467. https://doi.org/10.1016/j.pneurobio.2011.01.001
  7. Malykhin NV, Carter R, Seres P, Coupland NJ. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci. 2010;35:337-343. https://doi.org/10.1503/jpn.100002
  8. Hanson ND, Owens MJ, Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology. 2011;36:2589-2602. https://doi.org/10.1038/npp.2011.220
  9. Kays JL, Hurley RA, Taber KH. The dynamic Brain: Neyroplasticity and Mental Health. The Journal of Neuropsychiatry and Clinical Neurosciences. 2012;24:2:118-124. https://doi.org/10.1176/appi.neuropsych.12050109
  10. Bondy B. Dialogys in clinical neuroscience. 2002;4:7-20.
  11. Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression. Am J Geriatr Psychiatry. 2002;10:687-695. https://doi.org/10.1176/appi.ajgp.10.6.687
  12. Sexton CE, Le Masurier M, Allan ChL, et al. Magnetic resonance imaging in late-life depression: vascular and glucocorticoid cascade hypotheses. The British J of Psychiatry. 2012;201(1):46-51. https://doi.org/10.1192/bjp.bp.111.105361
  13. Bremer J. Carnitine-metabolism and functions. Physiol Rev. 1983;63:1420-1480. https://doi.org/10.1152/physrev.1983.63.4.1420
  14. Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, Leszek J, Gokhman D, Gasiorowski K, Bragin V, Aliev G. Mitochondrionspecific antioxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets. 2011;10(2):149-162. https://doi.org/10.2174/187152711794480474
  15. Gusev E, Skvortsova VI. Brain Ischemia. New York—Boston—Dordecht—London: Kluwer Academic/Plenum Publishers; 2003. https://doi.org/10.1007/978-1-4419-9248-2_4
  16. Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A, Neri S, Vacante M, Cammalleri L, Motta M. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr. 2008;46(2):181-190. https://doi.org/10.1016/j.archger.2007.03.012
  17. Chiechio S, Canonico PL, Grilli M. L-Acetylcarnitine: a mechanistically distinctive and potentially rapid-acting antidepressant drug. Int J Mol Sci. 2018;19(1):11. https://doi.org/10.3390/ijms19010011
  18. Calvani M, Arrigoni-Martelli E. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React. 1999;21:1-6.
  19. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer G, McClure R. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging. 1995;16:1-4. https://doi.org/10.1016/0197-4580(95)80001-8
  20. Zhang R, Zhang H, Zhang Z, Wang T, Niu J, Cui D, Xu S. Neuroprotective effects of pre-treatment with L-carnitine and acetyl-L-carnitine of ischemic injury in vivo and in vitro. Int J Mol Sci. 2012;13:2078-2090. https://doi.org/10.3390/ijms13022078
  21. Bersani G, Meco G, Denaro A, Liberati D, Colletti Ch, Nicolai R, Bersani FS, Koverech A. L-Acetylcarnitine in dysthymic disorder in eldery patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacology. 2013;23:1219-1225. https://doi.org/10.1016/j.euroneuro.2012.11.013
  22. Pattegrew JW, Levine J, McClure RJ. Acetyl-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry. 2000;5:616-632. https://doi.org/10.1038/sj.mp.4000805
  23. Rosca MG, Lemieux H, Hoppel CL. Mitochondria in eldery: is acetylcarnitine a rejuvenator? Adv Drug Deliver Rev. 2009;61(14):1332-1342. https://doi.org/10.1016/j.addr.2009.06.009
  24. Jones LL, McDonald DA, Borum PR. Acetylcarnitines: role in brain. Prog Lipid Res. 2010;49(1):61-75:8-10. https://doi.org/10.1016/j.plipres.2009.08.004
  25. Nasca C, Bigio B, Lee SL, Young SP, Kautz MM, Albright A, Beasley J, Millington DS, Mathé AA, Kocsis JH, Murrough JW, McEwen BS, Rasgon N. Acetyl-L-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci USA. 2018;115(34):8627-8632. https://doi.org/10.1073/pnas.1801609115
  26. Lau T, Bigio B, Zelli D, McEwen BS, Nasca C. Stress-induced structural plasticity of medial amygdala stellate neurons and rapid prevention by a candidate antidepressant. Mol Psychiatry. 2017;22(2):227-234. https://doi.org/10.1038/mp.2016.68
  27. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998;43:315-319. https://doi.org/10.1016/s0006-3223(97)00206-0
  28. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathe AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletti F. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA. 2013;110(12):4804-4809. https://doi.org/10.1073/pnas.1216100110
  29. Sheehan B, Karim S, Burns A. Mood disorders. In: Old age psychiatry. Oxford University Press. 2009;95-124. https://doi.org/10.1093/med/9780199216529.003.0004
  30. Katona C, Livingston G. How well do antidepressants work in older people? A systematic review of Number Needed to Treat. J Affective Disorders. 2002;69:47-52:22. https://doi.org/10.1016/s0165-0327(00)00332-3
  31. Van Straaten ICW, Scheltens P. Imaging abnormalities and depression in the elderly. Medicographia. 2003;25:68-71.
  32. Reppermund S, Zhuang L, Slavin MJ, Trollor JN, at al. White matter integrity and late-life depression in community-dwelling individuals: diffusion tensor imaging study using tract-based spatial statistics. The British J of Psychiatry. 2014;205(4):315-320. https://doi.org/10.1192/bjp.bp.113.142109
  33. Kalyn YaB, Gavrilova SI, Safarova TP, Yakovleva OB, Sheshenin VS. Novye vozmozhnosti optimizacii terapii depressij v gerontopsihiatricheskoj praktike. Farmateka. 2016;4(16):46-54. (In Russ.)
  34. Safarova TP, Yakovleva OB, Sheshenin VS, Kornilov VV, Shipilova ES. Novye puti optimizacii antidepressivnoj terapii pozhilyh depressivnyh bol’nyh v usloviyah gerontopsihiatricheskogo stacionara. Psihiatriya. 2017;3:5-13. (In Russ.)
  35. Safarova TP, Yakovleva OB, Sheshenin VS, Gavrilova SI. Metody augmentacii antidepressivnoj terapii (na modeli kompleksnoj terapii s vklyucheniem aktovegina) u pozhilyh bol’nyh gerontopsihiatricheskogo stacionara. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;2(6):55-63. https://doi.org/10.17116/jnevro201811806255
  36. Voronina TA, Ostrovskaya RU. Otchet ob eksperimental’nom izuchenii neiropsihotropnoi aktivnosti acetil-L-karnitina. M.: NII farmakologii RAMN; 2000.
  37. Frank E, Prien RF, Jarrett RB. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
  38. Mendlewicz J. Towards achieving remission in treatment of depression. Dialogues in Clinical Neuroscience. 2008;10:4:371-375.
  39. Gavrilova SI. Terapevticheskij potencial acetil-L-karnitina v lechenii kognitivnyh i depressivnyh rasstrojstv u pacientov pozhilogo vozrasta. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;6:2:37-45. https://doi.org/10.17116/jnevro201811806237
  40. Gavrilova SI, Kalyn YaB, Kolyhalov IV, Roshchina IF, Selezneva ND. Acetil-L-karnitin (karnicetin) v lechenii nachal’nyh stadij bolezni Al’cgejmera i sosudistoj demencii. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2011;9:16-22. (In Russ.)
  41. Fedorova YaB, Kolyhalov IV, Gavrilova SI. Opyt klinicheskogo primeneniya acetil-L-karnitina (Karnicetin) u pacientov s amnesticheskim tipom sindroma myagkogo kognitivnogo snizheniya. Nevrologiya. 2014;1:60-65. (In Russ.)
  42. Montgomery SA, Thai L, Amrein R. Meta-analysis of double-blind randomized controlled clinical trials of acetyl-L-camitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. M Clin Psychopharmacol. 2003;18:61-71. https://doi.org/10.1097/00004850-200303000-00001
  43. Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosomatic Medicine. 2018;80:154-159. https://doi.org/10.1097/psy.0000000000000537
  44. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Chi-Un Pae. A review of currentevidence for acetyl-L-carnitine in the treatment of depression. J Psychiatr Res. 2014;53:30-37. https://doi.org/10.1016/j.jpsychires.2014.02.005
  45. Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-L-carnitine. Ann NY Acad Sci. 2005;1053:153-161. https://doi.org/10.1038/sj.jcbfm.9591524.0037
  46. Chiappelli J, Rowland LM, Wijtenburg SA, Muellerklein F, Tagamets M, McMahon RP, Gaston F, Kochunov P, Hong LE. Evaluation of myo-inositol as a potential biomarker for depression in schizophrenia. Neuropsychopharmacology. 2015;40:2157-2164. https://doi.org/10.1038/npp.2015.57
  47. Nakamura J, Koh N, Sakakibara F, Hamada Y, Wakao T, Hara T, Mori K, Nakashima E, Naruse K, Hotta N. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats. J Pharmacol Exp Ther. 1998;287:897-902.
  48. Alves CJ, Fernandes E, de Lourdes Bastos M, Tavares MA, Summavielle T. Acetyl-L-carnitine provides effective in vivo neuroprotection over 3.4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience. 2009;158(2):514-523. https://doi.org/10.1016/j.neuroscience.2008.10.041
  49. Levine J, Kaplan Z, Pettegrew JW, McClure RJ, Gershon S, Buriakovsky I, Cohen H. Effect of intraperitoneal acetyl-L-carnitine (ALCAR) on anxiety-like behaviours in rats. Int J Neuropsychopharmacol. 2005;8(1):65-74. https://doi.org/10.1017/S1461145704004596
  50. Smeland OB, Meisingset TW, Borges K, Sonnewald U. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem Int. 2012;61:100-107. https://doi.org/10.1016/j.neuint.2012.04.008
  51. Tolu P, Masi F, Leggio B, et al. Effects of long-term acetyl-L-carnitine administration in rats: I. Increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology. 2002;27:410-420. https://doi.org/10.1016/s0893-133x(02)00306-8
  52. Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL, Grilli M. Upregulation of mGlu2 receptors via NF-xB p65 acetyla¬tion is involved in the proneurogenic and antidepressant effects of acetyl-L- carnitine. Neuropsychopharmacology. 2013;38:2220-2230. https://doi.org/10.1038/npp.2013.121
  53. Lau T, Bigio B, Zelli D, McEwen BS, Nasca C. Stress-induced structural plasticity of medial amygdala stellate neurons and rapid prevention by a candidate antidepressant. Mol Psychiatry. 2017;22:227-234. https://doi.org/10.1038/mp.2016.68

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.